176 related articles for article (PubMed ID: 28608814)
1. Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study.
Insua YV; Cámara J; Vázquez EB; Fernández A; Rivera FV; Silva MJVV; Barbazán J; Muinelo-Romay L; Folgar SC; Abalo A; López-López R; Abal M; Alonso-Alconada L
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28608814
[TBL] [Abstract][Full Text] [Related]
2. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
3. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
4. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.
Gorges TM; Stein A; Quidde J; Hauch S; Röck K; Riethdorf S; Joosse SA; Pantel K
PLoS One; 2016; 11(5):e0155126. PubMed ID: 27182774
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
9. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
Chou WC; Wu MH; Chang PH; Hsu HC; Chang GJ; Huang WK; Wu CE; Hsieh JC
Int J Biol Sci; 2018; 14(2):137-146. PubMed ID: 29483832
[No Abstract] [Full Text] [Related]
15. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
[TBL] [Abstract][Full Text] [Related]
17. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.
Schölch S; García SA; Iwata N; Niemietz T; Betzler AM; Nanduri LK; Bork U; Kahlert C; Thepkaysone ML; Swiersy A; Büchler MW; Reissfelder C; Weitz J; Rahbari NN
Oncotarget; 2016 May; 7(19):27232-42. PubMed ID: 27029058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]